Correlation of CD4+ T cell count with total lymphocyte count, haemoglobin and erythrocyte sedimentation rate levels in human immunodeficiency virus type-1 disease

Medical Journal Armed Forces India

Volumn 67, Issue 1, 2011, Pages 15-20

  Sen, Sourav ^a   Vyas, Akshat ^b   Sanghi, Sunil ^c   Shanmuganandan, K ^d   Gupta, R M ^e   Kapila, Ketoki ^f   Praharaj, A K ^a   Kumar, Satish ^a   Batra, R B ^a  

^a ARMED FORCES MEDICAL COLLEGE   (India)

^b Safdmjung Hospital   (India)

^c STI and HIV/AIDS CH (SC)   (India)

^d ARMY HOSPITAL RESEARCH AND REFERRAL   (India)

^e CH (NC)   (India)

^f NONE   (India)

Author keywords

Erythrocyte sedimentation rate; Haemoglobin; Human immunodeficiency virus; Total lymphocyte count

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HEMOGLOBIN;

ADULT; ANIMAL CELL; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSS-SECTIONAL STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PILOT STUDY; POPULATION RESEARCH; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TOTAL LYMPHOCYTE COUNT;

EID: 84055192668     PISSN: 03771237     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0377-1237(11)80005-5     Document Type: Article

References (22)

1. World Health Organization. Interim WHO Clinical Staging of HIV/AIDS and HIV/AIDS Case Definitions for Surveillance (Internet). 2005 (cited 2009). Available from: www.who.int/hiv/pub/guidelines/casedefinitions/en/index.html.
2. World Health Organization. Antiretrovira1 therapy for HIV infection in adults and adolescents: recommendations for a public health apporoach - 2010 rev. (Monograph online). Austria: WHO press; 2010. (cited 2010 July 17). Available from: http:/whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf.
3. National AIDS Control Organisation. Antiretroviral therapy guidelines for HIV-infected adults and adolescents including post-exposure prophylaxis (Monograph online). India: NACO, Ministry of Health and Family Welfare, Government of India; 2007. (Updated 2007 Aug 29; cited 2010 July 17). Available from: http://www.nacoonline.org/uploadl/Policies&Guidelines1.AntiretroviralTherapyGnidelinesforHIV-InfectedAdultsandAdolescentsIncludingPost-exposure.pdf.
4. WHO: Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach - 2003 revision (Monograph online). Swizerland: WHO press; 2004. (cited 2009 July 09). Available from: http://www.who.int/hiv/pub/prev_arvrevision2003en.pdf.
5. Anastos K, Shi Q, French AL, Levine A, Greenblatt RM, Williams C et al. Total lymphocyte count, haemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-l-infected women receiving highly active antiretroviral therapy. J Acqnir ln3mune Defic Syndr 2004; 35: 383-92.
6. Costello C, Nelson KE, Suriyanon V, Sennon S, Tovanabutra S, Heilig RM et al. HIV-I subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival. Int J Epidemiol 2005; 34: 577-84.
7. Lau B, Gange SJ, Phair JP, Riddler SA, Detels R, Margolick JB. Use of total lymphocyte count and haemoglobin concentration for monitoring progression of HIV infection. J Acquir Immune Defic Syndr 2005; 39: 620-5.
8. Gange SJ, Lau B, Phair J, Riddler SA, Detels R, Margolick J.B. Rapid declines in total lymphocyte count and hemoglobin in lllV infection begin at CD4 lymphocyte counts that justify antiretroviral therapy. AIDS 2003; 17: 119.
9. Ndakotsu MA, Salawu L, Durosinmi MA. Relation between erythrocyte sedimentation rate, clinical and immune status in HIV-infected patients. Niger J Med 2008; 17: 420-2.
10. Wessa P. Free Statistics Software, Office for Research Development and Education, version 1.1.23-r6 (updated 2010; cited 2010 July 12). Available from: http://www.wessa.net.
11. Eng J. ROC analysis: web-based calculator for ROC curves. Baltimore: Johns Hopkins University (updated 2006 May 17; cited 2009 Aug 12). Available from: http://www.jrocfit.org.
12. Spacek LA, Griswold M, Quinn TC, Moore RD. Total lymphocyte count and haemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. AIDS 2003; 17: 1311-7.
13. Badri M, Wood R. Usefulness of total lymphocyte count in monitoting highly active antiretrovira1 therapy in resource limited settings. AIDS 2003; 17: 541-5.
14. Mahajan AP, Hogan JW, Snyder B, Kumarasamy N, Mehta K, Solomon S et al. Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource-limited settings. J Acquir Immune Delic Syndr 2004; 36: 567-75.
15. World Health Organization. HIV/AIDS antiretrovira1 newsletter issue No. 13. Antiretroviral therapy in resource limited settings 2006 update. (Monograph ouline). Philipines: WHO press; December 2006. (cited 2009, July 10). Available from: http://www.wpro.who.int/NR/rdonlyres/BBC0070D-FD29-4871-B269-432B63A3160E/0/ARV_Newsletter_Issue_13.pdf.
16. Vázquez EĢ, de Górgolas M, Guerrero ML. Relation between erythrocyte sedimentation rate, clinical and immune status and virus load in non-hospitalized HIV-infected patients. Rev Esp Quimioter 2001; 14: 264-8.
17. Morpeth SC, Crump JA, Shao HJ, Ramadhani HO, Kiscnge PR, Moylan CA et al. AIDS Res Hum Retroviruses 2007; 23: 1230-6.
18. Moore DM, Awor A, Downing RS, Were W, Solberg P, Tu D et al. Deterntining eligibility for antiretrovira1 therapy in resource-limited settings using total lymphocyte counts, haemoglobin and body mass index. AIDS Res Ther 2007; 4: 1.
19. Gupta A, Gupte N, Bhosale R, Kakrani A, Kulkarni V, Nayak U et al. Low sensitivity of total lymphocyte count as a surrogate marker to identify antepartum and postpartum Indian women who require antiretroviral therapy. J Acquir Immune Delic Syndr 2007; 46: 338-42.
20. Chaudhary M, Kashyap B, Gautam H, Saini S, Bhalla P. Use of surrogate markers to predict the HIV diaease stage and time to initiate antirctroviral therapy in developing countries. J Int Assoc Physicians AIDS Care 2008; 7: 259-64.
21. Gitura B, Joshi MD, Lule GN, Anzala O. Total lymphocyte count as a surrogate marker for CD4+ t cell count in initiating antiretroviral therapy at Kenyatta National Hospital, Nairobi. East Air Med J 2007; 84: 466-72.
22. Daka D, Loha E. Relationship between Total Lymphocyte count (TLC) and CD4 count among peoples living with HIV, Southern Ethiopia: a retrospective evaluation. AIDS Res Ther 2008; 5: 26-31.